fulranumab Articles
USA’s FDA puts stops on Johnson & Johnson’s fulranumab and Regeneron/Sanofi-Aventis osteo drug due to side effect risks
4 January 2011
Showing 1-2 of 2 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
